Common Stock, par value $0.001
- Symbol
- CNSY
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Cerenome, Inc.
CNSYNASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events. On September 30, 2026, Cerenome, Inc. updated its corporate presentation for use in meetings with investors, analysts and others. A copy of certain updated slides is filed as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.
Company context
Plus Therapeutics is a U.S. pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (“CNS”) cancers. Our novel radiotherapeutic candidates are designed to deliver safe and effective doses of radiation to tumors. To achieve this, we have developed innovative approaches to drug formulation, including encapsulating radionuclides such as rhenium isotopes within nanoliposomes and microspheres. Our formulations are intended to achieve elevated patient-absorbed radiation doses and extend retention times such that the clearance of the isotope occurs after significant and essentially complete radiation decay, which will contribute and provide less normal tissue/organ exposure and improved safety margins.
Current securities
Recent company filings
- D filingSep 18, 2026
- Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities · Other EventsSep 10, 2026
- 10-Q filingAug 14, 2026
- Results of Operations and Financial ConditionAug 14, 2026
- Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearAug 4, 2026
Registered securities in this filing
CERENOME, INC. · 8-K · Filed 2026-10-02
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events.
On September 30, 2026, Cerenome, Inc. updated its corporate presentation for use in meetings with investors, analysts and others. A copy of certain updated slides is filed as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.
Filed exhibits (1)
Corporate Presentation (NASDAQ:CNSY) September 30, 2026 Exhibit 99.1 Introduction Regarding Forward Looking Statements This presentation of Cerenome, Inc. (the “Company”) contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this presentation other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “potential,” “anticipating,” “planning”, “projecting”, “expecting” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements about the Company’s anticipated expenditures, including research and development, and general and administrative expenses; the Company’s intent or ability to regain and maintain compliance…
Open exhibit ↗